Soft Tissue Leiomyosarcoma Clinical Trial
— LMS02Official title:
A Multicentric Phase II Trial Studying Efficacy of Doxorubicin Associated With Trabectedin (Yondelis) in First Line Treatment on Patients With Metastatic Leiomyosarcoma (Uterus or Soft Tissue) and/or Inoperable Relapse
| Verified date | January 2017 |
| Source | Gustave Roussy, Cancer Campus, Grand Paris |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Uterine leiomyosarcomas and soft tissues are rare tumors with a poor prognosis when
metastatic or locally advanced. They have an average chemosensitivity mainly to doxorubicin,
ifosfamide, cisplatin, gemcitabine and trabectedin but response rates in combination in
first line does not exceed 55% for uterine leiomyosarcomas and 35% for leiomyosarcomas of
soft tissue.
The trabectedin is a new cancer drug that has obtained marketing authorization after failure
of anthracyclines and ifosfamide in the treatment of soft tissue sarcomas (STM) in Europe.
It has especially shown efficacy in myxoid liposarcomas, leiomyosarcomas and synoviosarcoma.
This study aims to evaluate the usefulness of the combination of trabectedin with
doxorubicin in first-line treatment of uterine or soft tissue leiomyosarcoma.
| Status | Completed |
| Enrollment | 110 |
| Est. completion date | October 2016 |
| Est. primary completion date | January 2013 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 70 Years |
| Eligibility |
Inclusion Criteria: - Metastatic leiomyosarcoma (uterus or soft tissue) in inoperable relapse with no previous chemotherapy - At least one measurable lesion according to RECIST criteria before inclusion. At least one of the target is in a none irradiated area - Aged >/= 18 years and physiological age </= 70 years - PS </= 2 - Normal hematological function (Polymorphonuclear Neutrophils >/= 1500/mm3, platelets >/= 100 000/mm3) - Normal kidney function (creatinine < 1.5xN) - Creatinine phosphokinase </= 2.5xN - Normal hepatic function (total bilirubin </= 1xN; transaminase </= 2.5xN and alkaline phosphatase </= 1.5xN) - Cardiac function: normal echography and/or isotopic ventriculography (FR>30%, FEVG > 50%) - Patients able to procreate must use a birth control device during treatment and during 3 months after treatment for women; 5 months for men - Signed informed consent - Patient under affiliated to a system of care Exclusion Criteria: - Any other histological type of uterus sarcoma (carcinosarcoma...) or soft tissue - Specific contraindication to the treatment - Previous or evolutive mental disease - Previous cancer - Symptomatic or known brain metastasis - Previous radiotherapy ont he only measurable lesion - Previous allograft or autograft - Known positive serology (HIV, HbC, HbS) - Pregnant or breastfeeding women - Impossibility to follow the treatment for geographical, social or mental reason - Patients under legal protection |
| Country | Name | City | State |
|---|---|---|---|
| France | Gustave Roussy Cancer Campus Grand Paris | Villejuif | Val de Marne |
| Lead Sponsor | Collaborator |
|---|---|
| Gustave Roussy, Cancer Campus, Grand Paris |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Disease control rate | Disease control rate (objective response + stability) as defined by RECIST criteria | Assessed every 6 weeks from inclusion up to 6 months | |
| Secondary | Response rate | Assessed using RECIST criteria | Assessed every 6 weeks from inclusion up to 6 months | |
| Secondary | Progression Free Survival | Assessed every 6 weeks from inclusion up to 12 weeks |